PT - JOURNAL ARTICLE AU - Olav Engebraaten AU - Christina Yau AU - Kristian Berg AU - Elin Borgen AU - Øystein Garred AU - Maria E.B. Berstad AU - Ane S.V. Fremstedal AU - Angela De Michele AU - Laura van’t Veer AU - Laura Esserman AU - Anette Weyergang TI - RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer AID - 10.1101/2021.07.06.21255069 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.06.21255069 4099 - http://medrxiv.org/content/early/2021/07/07/2021.07.06.21255069.short 4100 - http://medrxiv.org/content/early/2021/07/07/2021.07.06.21255069.full AB - PURPOSE Targeted therapeutics strongly depends on validated biomarkers in order to select patients most likely to benefit from the treatment. HER2 serves as a predictive biomarker for HER2-targeted tyrosine kinase inhibitors and monoclonal antibodies. HER2 may, however, also be utilized as a transport gate for delivery of cytotoxic agents into the cell, such as for HER2-targeted antibody drug conjugates (ADCs; e.g. trastuzumab emtansine (T-DM1)). The predictive biomarkers for such ADCs may be more complex, also reflecting the intracellular transport.METHODS Five HER2-positive breast and ovarian cancer cell lines were evaluated with respect to T-DM1 sensitivity and correlated to the expression levels of proteins involved in endocytic trafficking including RAB4A, RAB5A and RAB11A, with possible impact on ADC pharmacology. The results were confirmed in a clinical cohort consisting of patients from the adaptive breast cancer clinical trial I-SPY2 where pathological complete response (pCR) was correlated to the RNA expression level of RAB4A, RAB5A and RAB11A. A subset of the clinical KAMILLA trial including 19 patients was used as a verification cohort where semi-quantitative IHC of RAB5A was correlated to progression free survival (PFS).RESULTS The early endosome marker RAB5A, was found to correlate positively to T-DM1 sensitivity in the cell line panel. Correlation between RAB5A expression and T-DM1 sensitivity (pCR) was confirmed in patients treated with trastuzumab emtansine/pertuzumab in the I-SPY2 trial, but not in the trastuzumab/paclitaxel control arm. The clinical correlation was verified in the patients from the KAMILLA trial where semi-quantitative RAB5A IHC staining correlated significantly positive to PFS.CONCLUSION The present results indicate that RAB5A is a predictive biomarker for T-DM1 and outline, for the first time, proteins involved in endocytic trafficking as predictive biomarkers for ADCs.Competing Interest StatementA patent application by Anette Weyergang, Kristian Berg, Olav Engebraaten and Maria E.B. Berstad, application number: WO 2018/234872 A1 is currently in national phase.Clinical TrialNCT01042379, NCT01702571Funding StatementWe thank the South-Eastern Norway Regional Health Authority for financial supportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Both the I-SPY 2 and Kamilla study complied with all relevant ethical regulations for work with human participants. The I-SPY2 study was approved by IRB boards at the participating study sites: *Institution: University of California San Diego Moores Cancer Center Name and address IRB: University of California, San Diego Human Research Protections Program Institutional Review Boards (Attn: Human Research Protections Program (HRPP) Altman Clinical and Translational Institute, Level 2 9452 Medical Center Drive La Jolla, CA 92093) *Institution: Georgetown University Lombardi Cancer Center Name and address: MedStar Health Research Institute-Georgetown University Oncology Institutional Review Board (Medical-Dental Building, SW104, 3900 Reservoir Road NW, Washington, DC 20057) *Institution: Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center Name and address: Loyola University Chicago Health Sciences Division Institutional Review Board for the Protection of Human Subjects (2160 South First Avenue Maywood, IL 60153) *Institution: University of California, San Francisco, Helen Diller Family of Comprehensive Cancer Center Name and address: UCSF Human Research Protection Program Institutional Review Board (490 Illinois Street, Floor 6, San Francisco, CA 94143) *Institution: University of Texas, Southwestern Medical Center Simmons Comprehensive Cancer Center Name and address: UT Southwestern IRB (5323 Harry Hines Blvd. Dallas, TX 75390) *Institution: H. Lee Moffitt Cancer Center and Research Institute Name and address: Chesapeake IRB (3181 SW Sam Jackson Park Road - L106RI Portland, OR 97239-3098) *Institution: Oregon Health and Science University Knight Cancer Institute Name and address: Oregon Health & Science University Research Integrity Office IRB (3181 SW Sam Jackson Park Road - L106RI, Portland, OR 97239-3098 *Institution: Mayo Clinic Breast Cancer Center - Rochester Name and address: Mayo Clinic Institutional Review Boards (201 Building, Room 4-60, 200 First St. SW, Rochester, MN 55905) *Institution: University of Pennsylvania, Abramson Cancer Center Name and address: University of Pennsylvania Office of Regulatory Affairs Institutional Review Board (3624 Market St., Suite 301 S, Philadelphia, PA 19104-6006) *Institution: University of Alabama at Birmingham Comprehensive Cancer Center Name and address: The University of Alabama at Birmingham Office of the Institutional Review Board for Human Use (470 Administration Building, 701 20th Street South, Birmingham, AL 35294-0104) *Institution: University of Minnesota, Masonic Cancer Center Name and address: University of Minnesota Human Research Protection Program (MMC 820 420 Delaware St. SE, Minneapolis, MN 55455-0392) *Institution: University of Colorado Cancer Center Name and address: Colorado Multiple Institutional Review Board (COMIRB) (University of Colorado, Anschutz Medical Campus, 13001 E. 17th Place, Building 500, Room N3214, Aurora, CO 80045) *Institution: University of Washington Medical Center Fred Hutchinson Cancer Research Center (FHCRC) IRB (Institutional Review Office 1100 Fairview Ave. N. Mail Stop J2-100, Seattle, WA 98109) *Institution: University of Southern California, Norris Comprehensive Cancer Center University of Southern California Health Sciences Institutional Review Board (LAC+USC Medical Center, General Hospital Suite 4700, 1200 North State Street, Los Angeles, CA 90033) *Institution: University of Texas, M.D. Anderson Cancer Center University of Texas MD Anderson Cancer Ctr Clinical IRBs (Office of Human Subjects Protection Unit 1637, 7007 Bertner Ave., Houston, TX 77030-3907) *Institution: Swedish Cancer Institute Western Institutional Review Board (WIRB) (1019 39th Avenue SE Suite 120, Puyallup, WA 98374-2115) *Institution: University of Arizona, Arizona Cancer Center at UMC and UMC-North University of Arizona Institutional Review Board (The University of Chicago Biological Sciences Division/University of Chicago Medical Center, 5751 S. Woodlawn Ave., 2nd floor, Chicago, IL 60637) All patients recruited in I-SPY2 signed an informed consent form.   The present study using the Kamilla samples was approved by the institutional research review board (Oslo University Hospital, Department of Cancer, Po Box 4953 Nydalen, 0424 Oslo), and the Regional Committees for Medical and Health Research Ethics (REC North-Secretariat, University of Tromsoe, Po Box 6050 Langnes, 9037 Tromsoe). The patients still alive at the time of collection of the data presented here, signed a separate informed consent form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe clinical data referred to in the manuscript is available in the supplementary file